Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP decreased its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 4.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,510,958 shares of the company’s stock after selling 103,371 shares during the quarter. Dimensional Fund Advisors LP owned about 1.17% of Hims & Hers Health worth $50,695,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Nisa Investment Advisors LLC raised its holdings in shares of Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares in the last quarter. Quest Partners LLC grew its holdings in Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after purchasing an additional 3,507 shares during the last quarter. Van ECK Associates Corp purchased a new stake in Hims & Hers Health in the 2nd quarter valued at approximately $111,000. Belpointe Asset Management LLC boosted its position in Hims & Hers Health by 10.0% during the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock worth $118,000 after acquiring an additional 1,205 shares during the last quarter. Finally, Daiwa Securities Group Inc. purchased a new position in shares of Hims & Hers Health during the 2nd quarter worth about $142,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Up 0.3 %

Hims & Hers Health stock opened at $17.77 on Monday. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $25.74. The stock has a market cap of $3.82 billion, a price-to-earnings ratio of -1,777.00 and a beta of 1.05. The business has a 50-day simple moving average of $16.93 and a 200 day simple moving average of $17.19.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The company had revenue of $315.65 million for the quarter, compared to analysts’ expectations of $302.43 million. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. Hims & Hers Health’s revenue for the quarter was up 51.8% compared to the same quarter last year. During the same period last year, the firm posted ($0.03) EPS. On average, research analysts anticipate that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on HIMS shares. Jefferies Financial Group boosted their target price on Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, June 27th. Deutsche Bank Aktiengesellschaft increased their price target on Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a research note on Wednesday, August 7th. Piper Sandler restated a “neutral” rating and set a $18.00 target price on shares of Hims & Hers Health in a report on Tuesday, August 6th. Truist Financial upped their price target on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, July 18th. Finally, Imperial Capital downgraded shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $19.86.

Insider Buying and Selling

In related news, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total value of $2,750,209.28. Following the sale, the chief executive officer now owns 33,502 shares in the company, valued at $487,789.12. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, insider Soleil Boughton sold 2,335 shares of the stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $20.28, for a total transaction of $47,353.80. Following the sale, the insider now directly owns 169,144 shares of the company’s stock, valued at approximately $3,430,240.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the transaction, the chief executive officer now owns 33,502 shares of the company’s stock, valued at $487,789.12. The disclosure for this sale can be found here. Insiders have sold a total of 731,473 shares of company stock valued at $12,671,277 over the last three months. 17.71% of the stock is owned by company insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.